修美乐联合麻防犀角地黄汤对中重度斑块型银屑病的临床疗效及相关免疫炎症指标的影响  

Study on Clinical Effect of Humira Combined with Mafang Xijiao Dihuang Decoction(麻防犀角地黄汤) on Moderate to Severe Plaque Psoriasis

作　　者：屠远辉[1] 吴涛[2] 刘爱民[1] 张步鑫[1] TU Yuanhui;WU Tao;LIU Aimin;ZHANG Buxin(Henan Hospital of Traditional Chinese Medicine,Zhengzhou 450000,Henan,China;The First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450000,Henan,China)

机构地区：[1]河南省中医院,河南郑州450000 [2]河南中医药大学第一附属医院,河南郑州450000

出　　处：《中华中医药学刊》2021年第5期57-59,共3页Chinese Archives of Traditional Chinese Medicine

基　　金：国家自然科学基金面上项目(81874471)。

摘　　要：目的探究修美乐联合麻防犀角地黄汤对中重度斑块型银屑病的临床疗效及对相关免疫炎症指标的影响。方法选择2019年1月—2019年12月收治的72例重度斑块型银屑病患者,随机将患者分为对照组和治疗组,每组36例,对照组给予修美乐皮下注射治疗,治疗组在对照组的基础上联合麻防犀角地黄汤进行治疗,治疗12周,观察两组患者的临床总有效率、银屑病面积与严重程度指数(PASI)评分、生活质量指数(DLQI)评分、血清炎性因子水平及不良反应发生情况。结果对照组临床总有效率为86.11%,治疗组临床总有效率为97.22%(P<0.05);治疗后,两组患者PASI评分、DLQI评分均显著降低(P<0.05),治疗组明显低于对照组(P<0.05);两组患者IL-2、IL-17、IL-23、TNF-α水平均显著降低(P<0.05),治疗组明显低于对照组(P<0.05);两组患者均无严重不良反应,差异无统计学意义(P>0.05)。结论修美乐联合麻防犀角地黄汤对中重度斑块型银屑病疗效确切,可有效减轻患者银屑病面积,提高生活质量,且在治疗过程中,无严重不良反应,安全有效,值得在临床上推广应用。Objective The clinical effect of Mafang Xijiao Dihuang Decoction(麻防犀角地黄汤,MXDD) combined with Humira on moderate to severe plaque psoriasis. Methods Seventy-two patients with severe plaque psoriasis treated from January 2019 to December 2019 were randomly divided into a control group and a treatment group, with 36 cases in each group. The control group was given Humira by subcutaneous injection. The treatment group was combined with MXDD for treatment on the basis of the control group. After 12 weeks of treatment, the total clinical effectiveness, psoriasis area, severity index(PASI) score, quality of life index(DLQI), levels of serum inflammatory factors and occurrence of adverse reactions of the two groups were compared. Results The total clinical effective rate was 86.11% in the control group and 97.22% in the treatment group(P<0.05). After treatment, the PASI score and DLQI score of the two groups were significantly reduced(P<0.05), and the treatment group’s score was significantly lower than that of the control group(P<0.05). The levels of IL-2, IL-17, IL-23 and TNF-α in the two groups were significantly reduced(P<0.05), and the treatment group’s levels were significantly lower than those in the control group(P<0.05). There were no serious adverse reactions in the two groups. The difference was not statistically significant(P>0.05). Conclusion MXDD combined with Humira is effective in the treatment of moderate to severe plaque psoriasis. It can effectively reduce the area of psoriasis and improve the quality of life of patients. In the course of treatment, there are no serious adverse reactions. It is safe and effective, worthy of clinical application.

关 键 词：麻防犀角地黄汤 修美乐 中重度斑块型银屑病 联合治疗 PASI评分 

分 类 号：R275.958.63[医药卫生—中西医结合]